Current and Future State of Cardiovascular Disease and Type 2 Diabetes Series

Cardiovascular disease (CVD) is the leading cause of death and a major cause of morbidity and mortality for people living with type 2 diabetes. A recent survey by the American Heart Association and the American Diabetes Association showed that only half of people age 45 and older with type 2 diabetes recognize their increased risk or have discussed their risk with their healthcare providers. The three educational activities follow the progression of cardiovascular disease from early/pre-diabetes to advancing/progressive disease to late stage/managing advanced complications.

Activities
Current and Future State of Cardiovascular Disease and Type 2 Diabetes: Case 1: Prediabetes and Cardiovascular Risks: A Primary Call To Action | 1.0 Credit
Current and Future State of Cardiovascular Disease and Type 2 Diabetes: Case 2: Patient-Centered Management of Diabetes and Prevention of Cardiovascular Disease | 1.0 Credit
Current and Future State of Cardiovascular Disease and Type 2 Diabetes: Case 3: Managing Macrovascular Complications In Patients with Diabetes | 1.0 Credit


Learning Objectives
  • Discuss the epidemiology of prediabetes and diabetes
  • Review risk factors, screening tools, and diagnostic criteria for prediabetes and diabetes
  • Describe the pathophysiology and complications of prediabetes
  • Analyze the relationship between prediabetes and cardiovascular disease
  • Develop and implement screening strategies for a patient presenting with prediabetes
  • Formulate an evidence-based treatment plan for patients with prediabetes including lifestyle and pharmacologic interventions
  • Discuss prevalence and associations of diabetes, cardiovascular disorders (CVD), and diabetic kidney disease (DKD)
  • Recognize diabetes as a CVD equivalent and accelerator
  • Review behavioral interventions for mitigating CVD and DKD risk in type 2 diabetes mellitus (T2DM)
  • Distinguish major drug classes and outcomes from cardiovascular outcome trials (CVOTs) related to impacts on glycemic control, CVD, and DKD risk reduction in T2DM
  • Develop clinical strategies using CVOT drug classes to optimize glycemic goals and reduce CVD and DKD risk for patients with T2DM
  • Implement a team approach to diabetes care encouraging patient-centered diabetes self-management skills, education, and support (DSMES)
  • Summarize the associations of T2DM, cardiovascular (CVD), and diabetic kidney disease (DKD) and implications to the progression of cardiorenal syndrome (CRS) and cardiovascular mortality
  • Apply cardiovascular outcome trial (CVOT) results to provide guidance on appropriate pharmacologic interventions for patients with advanced diabetes related complications
  • Analyze the impact of hypoglycemia in patients with advanced coronary artery disease and discuss techniques for mitigating risk of hypoglycemia
  • Employ tools and techniques to improve adherence and long-term chronic disease outcomes

AAPA offers no returns or refunds for online CME activities purchased via the AAPA store. All sales are final.